OEV-143 Monitors

Products	OEV-143 Monitors
Company	Olympus America Medical
Item	OEV-143 Monitors
Features	Analog RGB, Y/C, and composite video inputs, easy-to-operate, on-screen menu simplifies control functions. Control knobs offer convenient access to settings for contrast, brightness, aperture, phase and chroma. RGB split screen mode allows two RGB inputs to be observed simultaneously, ideal for setting printer color. Normal, overscan and underscan modes provide for a variety of image sizes. Safe design and cover for front panel prevents accidental setting changes.
Description	The OEV-143 Monitors are designed exclusively for video endoscopy and are ideal components for use with all Olympus endoscopy systems. When used in conjunction with our innovative endoscopic equipment, the OEV-143 provides sharp, high-resolution images with excellent color reproduction to provide you with the view - and details - necessary for accurate diagnosis. They provide great image flexibility thanks to a variety of adjustable features - controlled via conveniently located front panel knobs - and are easy to operate due to a simplified on-screen menu.
Info	Olympus America Medical Customer Service: (800) 848-9024 Web site: http://www.olympusamerica.com

Related medicine products :

1. Video Monitors
2. OEV-203 Monitors
3. Screenline LCD Monitors

TAG: OEV Monitors

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

Medicine Products:

Phenacemide, Urine PFGE Pethidine Persantine

(Date:12/14/2009)... Adults, Attitudes and Behavior Regarding Pregnancy, Contraception, and Related ... Nearly all unmarried young adults ages 18-29 believe pregnancy ... and 86% of women) and say that it is ... (86% of men and 88% of women), according to ... Teen and Unplanned Pregnancy. Even so: ,, ...

(Date:12/14/2009)... oxygen, drugs, and more… , ... ... in collaboration with scientists at University of Michigan, have developed ... of natural red blood cells, including softness, flexibility, and the ... primary function of natural red blood cells is to carry ...

(Date:12/14/2009)... ARBOR, Mich., Dec. 14 Pepsi ... the Commonwealth of Kentucky are among the major ... this fall to help their employees make better ... solution gives employees a personalized summary of their ... of that care. With this personalized information, employees ...

(Date:12/14/2009)... -- Americold Realty Trust ("Americold") announced today that it ... the U.S. Securities and Exchange Commission (the "SEC") relating ... shares. The number of shares to be offered and ... been determined. The common shares to be sold in ... ,, The joint book-running managers of the offering ...

(Date:12/14/2009)... BRAINTREE, Mass., Dec. 14 Haemonetics Corporation ... it has filed a new legal action to ... Fenwal,s just released red cell collection kits, using ... its separation chamber to circumvent Haemonetics, patent and ... continued sale of infringing products after December 1, ...

Breaking Medicine News(10 mins):Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 2 Health News:Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference 3 Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2 Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2 Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3

[1] Although Most Unmarried Young Adults Want to Avoid Pregnancy, Many Don't Use Contraception, Know Little About It, and Think It Doesn't Make Much Difference [0] Synthetic Red Blood Cells Developed [0] Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process [0] Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering [0] Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement

... SAN DIEGO, Nov. 24 Volcano Corporation (Nasdaq: VOLC ... for the diagnosis and treatment of coronary and peripheral artery disease, ... Piper Jaffray Health Care Conference on Tuesday, December 2. , ... and chief executive officer, will begin at 1:30 p.m., Eastern Standard ...

... Calif., Nov. 24 Thoratec Corporation,(Nasdaq: THOR ... to save, support and restore falling hearts, said today ... Jaffray Heath Care Conference on,Wednesday, December 3. , ... provide an,update on the company, beginning at 1 p.m., ...

... Networks, Inc.(TM), the,company delivering new technology in enterprise ... Networks executive Amit Chawla as its new President,and ... Agito Networks, flagship product is the ... IP telephony, and,location information, improving the accessibility and ...

... Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of ... , King Extends Tender Offer Through December 19, 2008 ... BRIDGEWATER, N.J., Nov. 24 King Pharmaceuticals, Inc. (NYSE: ... announced that the two companies have signed a definitive merger agreement ...

... with Broad Potential to Treat Life-Threatening Viral Infections-- , ... and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models-- ... is a ,Druggable, Target Common to a Number of Serious ... Calif., Nov. 24 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) ...

... summarized- , , ... Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian ... Cell Wall-DNA Complex (MCC) - trademarked Urocidin - ... 2008 Societe Internationale d,Urologie (SIU) Congress in Santiago, ...

Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast Thoratec Presentation at Piper Jaffary Conference to be Webcast Agito Networks Names New CEO, Broadens Depth of Experience of Enterprise Mobility Leader King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

(Date:12/15/2009)... Genomic Health, Inc. (Nasdaq: GHDX ) ... Onco type DX® breast cancer test, a multi-gene ... likelihood of chemotherapy benefit and recurrence risk for patients ... the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, ... TX. ,, "The breadth of data presented at last ...

(Date:12/15/2009)... Arlington Medical Resources (AMR) and Decision ... (MRSA) is the most concerning pathogen to surveyed ... treatment of skin and skin structure infections. A ... factors that influences European physician drug selection for ... factors that drive prescribing include an agent,s skin ...

(Date:12/15/2009)... INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... ), Eli Lilly and Company (NYSE: ... ) today announced positive results from a head-to-head ... therapy, to BYETTA® (exenatide) injection taken twice daily, ... weeks of treatment, patients taking exenatide once weekly ...

Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6 Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2 A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6 Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7 Study Forecasts More Young Doctors in Future 59852 1 Study Forecasts More Young Doctors in Future 59852 2 Experimental treatments restore partial vision to blind people 10444 1 Experimental treatments restore partial vision to blind people 10444 2 Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 1 Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 2

[0] Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations [0] A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections [0] Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study